Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis.

Abstract

BACKGROUND AND AIMS:

Plasminogen activator inhibitor type 1 (PAI-1) is associated with poor prognosis in breast cancer. Transcriptional expression of the PAI-1 can be controlled by PAI-1 promoter 4G/5G polymorphism. However, the significance of PAI-1 promoter 4G/5G polymorphism in breast cancer patients is contentious. To address this controversy, we conducted a meta-analysis for the relationships between PAI-1 promoter polymorphism and clinicopathological characteristics of breast cancer.

METHODS:

Relevant published studies were identified using a search of PubMed, Embase, and the ISI Web of Science. The effect sizes of PAI-1 promoter 4G/5G polymorphism on breast cancer risk, lymph node metastasis, histologic grade, and overall survival were calculated by odds ratio (OR) or hazard ratio. The effect sizes were combined using a random-effects model.

RESULTS:

Individuals with 4G/4G genotype had a higher risk of breast cancer than those with the combined 4G/5G and 5G/5G genotypes (OR = 1.388; p = 0.031). Breast cancer patients with the 5G/5G genotype displayed lymph node metastasis more than patients with either the combined other genotypes (OR = 1.495; p = 0.027) or with the 4G/4G genotype (OR = 1.623; p = 0.018). However, the PAI-1 promoter 4G/5G polymorphism was not associated with histological grade or overall survival.

CONCLUSIONS:

PAI-1 promoter 4G/5G polymorphism is associated with a relatively increased risk of breast cancer development and lymph node metastasis.

• Authors: Ju-Han Lee, Younghye Kim, Jung-Woo Choi, Young-Sik Kim
• Journal: Archives of medical research (Arch Med Res) Vol. 44 Issue 1 Pg. 39-45 (Jan 2013) ISSN: 1873-5487 [Electronic] United States
• PMID: 23291383 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2013 IMSS. Published by Elsevier Inc. All rights reserved.

Chemical References

• Plasminogen Activator Inhibitor 1
• SERPINE1 protein, human

Topics

• Breast Neoplasms (genetics, pathology)
• Female
• Genetic Predisposition to Disease
• Genotype
• Humans
• Lymphatic Metastasis (genetics)
• Odds Ratio
• Plasminogen Activator Inhibitor 1 (genetics)
• Polymorphism, Genetic
• Promoter Regions, Genetic (genetics)
• White People (genetics)